Art Krieg, Checkmate
July 20, 2020 06:51 AM EDTUpdated 10:37 AM
Financing
R&D

Art Krieg’s Check­mate ex­e­cutes a snap­py 1-2 biotech gam­bit — big crossover fol­lowed by an in­stant IPO

John Carroll

Editor & Founder

Just as ex­pect­ed, Check­mate’s $85 mil­lion ven­ture raise a few weeks ago was a pre­quel to the lat­est biotech IPO to hit the queue …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times